Abstract
AbstractExtracting valuable insights from high-throughput biological data of Alzheimer’s disease to enhance understanding of its pathogenesis is becoming increasingly important. We engaged in a comprehensive collection and assessment of Alzheimer’s microarray datasets GSE5281 and GSE122063 and single-cell data from GSE157827 from the NCBI GEO database. The datasets were selected based on stringent screening criteria: a P-value of less than 0.05 and an absolute log fold change (|logFC|) greater than 1. Our methodology involved utilizing machine learning algorithms, efficiently identified characteristic genes. This was followed by an in-depth immune cell infiltration analysis of these genes, gene set enrichment analysis (GSEA) to elucidate differential pathways, and exploration of regulatory networks. Subsequently, we applied the Connectivity Map (cMap) approach for drug prediction and undertook single-cell expression analysis. The outcomes revealed that the top four characteristic genes, selected based on their accuracy, exhibited a profound correlation with the Alzheimer’s disease (AD) group in terms of immune infiltration levels and pathways. These genes also showed significant associations with multiple AD-related genes, enhancing the potential pathogenic mechanisms through regulatory network analysis and single-cell expression profiling. Identified three subpopulations of astrocytes in late-stage of AD Prefrontal cortex dataset. Discovering dysregulation of the expression of the AD disease-related pathway maf/nrf2 in these cell subpopulations Ultimately, we identified a potential therapeutic drug score, offering promising avenues for future Alzheimer’s disease treatment strategies.
Publisher
Cold Spring Harbor Laboratory
Reference73 articles.
1. Bob Jones and Cindy Miller. Systems Biology of Alzheimer’s Disease Protocol Alzheimer’s as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks Juan I. In Systems Biology of Alzheimer’s Disease. 123–145. New York: XYZ Press,
2. Neuropathological Alterations in Alzheimer Disease
3. Alzheimer's disease: The right drug, the right time
4. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies;Nature Clinical Practice Oncology volume,2008
5. Understanding disease progression and improving Alzheimer’s disease clinical trials: Recent highlights from the Alzheimer’s Disease Neuroimaging Initiative;Alzheimer’s Disease Neuroimaging Initiative;Alzheimer’s & Dementia,2019